This research was supported in part by grants from the Karolinska Institute.
Carbohydrate-Deficient Transferrin and Gamma-Glutamyl Transferase Levels during Disulfiram Therapy
Article first published online: 11 APR 2006
Alcoholism: Clinical and Experimental Research
Volume 20, Issue 7, pages 1202–1205, October 1996
How to Cite
Helander, A. and Carlsson, S. (1996), Carbohydrate-Deficient Transferrin and Gamma-Glutamyl Transferase Levels during Disulfiram Therapy. Alcoholism: Clinical and Experimental Research, 20: 1202–1205. doi: 10.1111/j.1530-0277.1996.tb01112.x
- Issue published online: 11 APR 2006
- Article first published online: 11 APR 2006
- Received for publication March 29, 1996; accepted June 19, 1996
- Biochemical Markers;
Serum samples for quantification of carbohydrate-deficient transferrin (CDT) and γ-glutamyl transferase (GGT) were collected from alcohol-dependent men and women upon admission to the hospital for detoxification, and repeatedly over a 3- to 5-week period of supervised disulfiram administration as outpatients. On admission, 10 of 12 patients showed CDT concentrations above the conventional cutoff limits, whereas 6 had elevated GGT values. Normalization usually occurred within 1 to 3 weeks of disulfiram treatment, after which CDT and GGT leveled out at a relatively stable individual baseline level. However, in those patients with the highest values on admission, the decline continued during the entire observation period. The time for normalization of GGT was typically longer than for CDT. In four male patients who had taken disulfiram regularly (400–800 mg every second or third day) for at least 3 months before entering the study, the CDT and GGT concentrations were stable over time and all fell within normal limits. The present results indicate that disulfiram treatment does not influence the serum level of CDT. It is also suggested that consecutive CDT and GGT measurements during outpatient treatment with disulfiram after detoxification can be used to identify the individual baseline (Le., abstinence) values for CDT and GGT, and, furthermore, for monitoring treatment outcome.